Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995 –2015

We described myelosuppressive chemotherapy changes by febrile neutropenia (FN) risk category (high, i ntermediate, unclassified), PP-CSF use, and, in the first cycle of myelosuppressive chemotherapy, neutropenia-related hospitalization (ICD-9-CM: 288.0X, first 5 positions). We evaluated hospitalization trends using a logistic regression model with spline curve of calendar year adjusting for baseline characteristics.ResultsAnnual cohorts included 1451 –2114 eligible patients for 1995–2007 and 5272–7603 for 2008–2015. Myelosuppressive chemotherapy use with high/intermediate FN risk increased from 31% in 1995 to 56% in 1999, stabilized through 2008 (range 56–61%), then decreased to 52% in 2015. PP-CSF use increased from 5.5% in 1995 to 52 .7% in 2015, mainly due to pegfilgrastim introduction in 2002. Crude neutropenia-related hospitalization incidence decreased from 5.2% in 1995 to 2.7% in 2015; adjusted incidence decreased, on average, by 4.7% yearly before 2010 (p 
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

In conclusion, the spatial features of dose distribution extracted by the dosiomics method effectively improves the prediction ability. Introduction Radiation pneumonitis (RP) is one of the major toxicities of thoracic radiation therapy. The clinical symptoms range from fever, cough to pulmonary function failure, which may occur during the first 6 months after irradiation. Reducing the prescription dose could lower the risk of RP incidence, but also impairs tumor control. An accurate RP predictor (or prediction model) is desired to “safely” irradiate the tumor target without increasing the risk of RP in...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Lipegfilgrastim administered to patients with solid tumor/NHL undergoing chemotherapy in routine clinical practice showed similar effectiveness and safety compared to the pivotal trials. PMID: 30557099 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
CONCLUSIONS: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high-risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. PMID: 30550346 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Objective: To investigate the clinical features of 2nd hematological malignancies post to the initial cancer treatment.METHODS: A retrospective study was performed to analyze the available clinical data of 116 patients diagnosed with 2nd hematologic malignancies after treatment of various malignant tumors from June 1998 to June 2018 at Sun Yat-sen University cancer center.RESULTS: The characteristics of the 116 patients diagnosed with 2nd hematological cancer post to initial cancer treatment were indicated as following: 62 males and 54 females. The primary tumor category was grouped as (according to ICD-10 International Di...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions Source Type: research
In this study, we examined the impact patient travel burden has on administration of prophylactic G-CSFs and the subsequent impact on FN incidence. METHODS: Medicare claims data were used to identify a cohort of beneficiaries age 65+ with non-myeloid cancers at high risk for FN between January 2012 and December 2014. Driving distance and time were calculated from patient residence ZIP code to the location of G-CSF and/or chemotherapy administration. Regression models were used to estimate the odds of G-CSF prophylaxis relative to patient driving distance and time, and odds of FN incidence relative to timing of G-CSF ad...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Abstract PURPOSE: The current shift in site of care from community oncology practices to the hospital outpatient department to deliver oncology services may have significant implications for the economic and clinical outcomes of cancer care. Therefore, this study compares health care use and costs among patients with cancer receiving intravenous (IV) chemotherapy in physician offices (PO) versus in hospital outpatient settings (HOP). METHODS: This retrospective study, which was based on medical and pharmacy claims data, included patients (age, 18 to 64 years) initiating IV chemotherapy/biologic treatment betw...
Source: JOP - Category: Gastroenterology Authors: Tags: J Oncol Pract Source Type: research
On the first day of spring 2007, Francesca Giessmann, 43, a marketing executive and holistic health coach from Kirkland, Washington, was rushed to the emergency room with severe stomach pain. After running numerous tests, doctors gave her the diagnosis of stage 3 non-Hodgkin lymphoma. Shocked and saddened by the news of her cancer, Giessmann's thoughts quickly turned to her son, Leo, who'd turned 3 years old the month prior. "Leo was very young and could not fully understand what was going on," Giessmann said. "Our pediatrician suggested we try to keep everything normal. I spent a great deal of time in be...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
This article presents pooled clinical data for tbo-filgrastim compared with Neupogen® (Amgen, Thousand Oaks, CA, USA) as well as tbo-filgrastim post-marketing safety data. The safety and efficacy of tbo-filgrastim were evaluated in three phase III studies in 677 patients receiving myelosuppressive chemotherapy and study drug (348 patients with breast cancer, 237 with lung cancer, 92 with non-Hodgkin lymphoma). In each study, the efficacy of tbo-filgrastim was similar to that of Neupogen. Overall, 633 (93.5 %) patients receiving the study drug experienced 6093 treatment-emergent adverse events (AEs), most of which ...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Abstract Tbo-filgrastim (filgrastim XM02; Biograstim®, Ratiograstim®, Tevagrastim®) is approved in the EU as a biosimilar of filgrastim (Neupogen®) for use in all indications for which reference filgrastim is approved, including chemotherapy-induced neutropenia, neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation, mobilization of peripheral blood stem cells (PBSCs), severe chronic neutropenia, and neutropenia in HIV infection. Tbo-filgrastim (Granix®) is also approved as a biologic in the USA for neutropenia associated with chemotherapy. Tbo-filgrast...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Conclusion: Lipegfilgrastim was effective and safe when administered for the prevention of chemotherapy-induced neutropenia under real-world conditions.Oncol Res Treat 2015;38:221-229
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Lymphoma | Medicare | Non-Hodgkin's Lymphoma | Study